Substance / Medication

Vortioxetine

Overview

Active Ingredient
vortioxetine
RxNorm CUI
1455099

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Use of vortioxetine in different neurological fields: a systematic review and future perspectives.
Verrienti Giulio, Colonna Isabella, Raccagni Cecilia · Neurol Sci · 2025
PMID: 39808348Meta-Analysis
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis.
Vijayan Souganya, Ramanathan Barath, Mohan Reenaa et al. · J Psychopharmacol · 2025
PMID: 41058029Meta-Analysis
Safety and tolerability of vortioxetine versus serotonin reuptake inhibitors in late life depression: A systematic review and meta-analysis.
Rodrigues Alessi Mateus, Barroso Douglas, Cerchi Barbosa Eduardo et al. · Asian J Psychiatr · 2025
PMID: 40073578Meta-Analysis
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis.
Berardelli Isabella, Rogante Elena, Formica Federico et al. · J Psychopharmacol · 2025
PMID: 39891526Meta-Analysis
Vortioxetine versus reuptake inhibitors in adults with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
Barbosa Eduardo Cerchi, da Silva Giovanna Hanike Santos, Sbardelotto Ângelo Eduardo Espíndola et al. · Asian J Psychiatr · 2024
PMID: 39276484Meta-Analysis
Vortioxetine for depression in adults: A systematic review and dose-response meta-analysis of randomized controlled trials.
Yang Xin, Fang Shuping, Lyu Wenqi et al. · Psychiatry Clin Neurosci · 2024
PMID: 38957929Meta-Analysis
The dose-response relationship of vortioxetine on major depressive disorder: an umbrella review.
Wang Ping, Wang Wei-Wei, Liu Yi-Qi et al. · Psychiatry Res · 2024
PMID: 39121757Meta-Analysis
Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults.
Zhang Xinyan, Cai Yuchun, Hu Xiaowen et al. · Front Psychiatry · 2022
PMID: 35815048Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vortioxetine (substance)
SNOMED CT
708717008
UMLS CUI
C3661282
RxNorm CUI
1455099

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.